Source comparison
PT-141 Cycle Structure: Protocol Comparison
Clinical Trial Standard 2x/week, 48hr spacing 8 weeks 4 weeks off High. Receptor density preserved across 24-week trials Nausea 10–15%, flushing 8% Gold standard for long-term use; balances efficacy with safety Aggressive User Protocol 3–4x/week 6 weeks 2 week
This comparison does not assign a generated winner or score.
- Clinical Trial Standard
- 2x/week, 48hr spacing
- 8 weeks
- 4 weeks off
- High. Receptor density preserved across 24-week trials
- Nausea 10–15%, flushing 8%
- Gold standard for long-term use; balances efficacy with safety
- Aggressive User Protocol
- 3–4x/week
- 6 weeks
- 2 weeks off
- Moderate. Diminishing response by week 6
- Nausea 25–30%, persistent flushing
- Unsustainable; users typically abandon or escalate dose by week 8
- Conservative Maintenance
- 1x/week
- 12 weeks
- Excellent. Users report stable response for 12+ months
- Nausea <5%, minimal flushing
- Best for long-term therapeutic use; lowest side effect burden
- Event-Driven (Sporadic)
- As-needed, ≥72hr gaps
- No fixed cycle
- Not required
- Excellent. No tolerance development
- Minimal. Side effects per-use only
- Ideal for users seeking spontaneity without daily commitment